AC-Selank-NH2 10mg (N-Acetyl Selank Amidate)

Description

Disclaimer: AC-Selank-NH2 (N-Acetyl Selank Amidate) is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is intended strictly for laboratory and research purposes only.

What is AC-Selank-NH2 Peptide?

AC-Selank-NH2, also known as N-Acetyl Selank Amidate, is a synthetically modified analog of Selank. Selank is a synthetic derivative of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence to improve metabolic stability. AC-Selank-NH2 incorporates two further modifications: N-terminal acetylation (Ac-) and C-terminal amidation (-NH2). Both are associated with increased resistance to enzymatic hydrolysis in experimental settings. It is studied in research models in the context of GABAergic pathway modulation, enkephalinase inhibition, and neurological functional connectivity.

Properties of AC-Selank-NH2

Property	Details
CAS Number	2212313-10-6 (N-Acetyl Selank Amidate, confirmed) Parent Selank CAS (reference): 129954-34-3
Molar Mass	793.9 g/mol (estimated for acetylated/amidated form; parent Selank: 751.887 g/mol)
PubChem CID	133082488 (N-Acetyl Selank, confirmed) Parent Selank PubChem CID (reference): 11765600
Chemical Formula	C35H59N11O10 (estimated for AC-NH2 modified form; parent Selank: C33H57N11O9)
IUPAC	(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)- 2-acetamido-3-hydroxybutanoyl]amino]-6-aminohexanoyl] pyrrolidine-2-carbonyl]amino]-5- (diaminomethylideneamino)pentanoyl]pyrrolidine-2- carbonyl]amino]acetyl]pyrrolidine-2-carboxamide [Verify terminal group against CAS 2212313-10-6 on PubChem before publishing]
Stability/ Shelf life	24 months when stored lyophilized at −20 °C under recommended conditions
Synonyms	N-Acetyl Selank Amidate, Acetyl-Selank-NH2, AC-Selank Amidate
Storage Instructions	−20 °C (lyophilized)
Amino Acid Sequence	Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2
Wada Status	Not explicitly listed on the WADA 2026 Prohibited List

How Does AC-Selank-NH2 Peptide Work?

AC-Selank-NH2 shares the core heptapeptide sequence of Selank and is thought to act through similar mechanisms in experimental models. The N-terminal acetylation and C-terminal amidation modifications are associated with protection against aminopeptidase and carboxypeptidase degradation, respectively, potentially extending the compound’s stability in experimental systems relative to the parent molecule.

 

Based on articles retrieved from PubMed, Selank and its analogs are thought to influence the following pathways in experimental models:

• Positive allosteric modulation of GABA-A receptor binding, studied using radioligand-receptor methods in rat brain membrane preparations
• Modulation of enkephalin-degrading enzyme activity, associated with prolonged leu-enkephalin half-life in plasma in preclinical models
• Dopaminergic system modulation is proposed to operate through the endogenous opioid system rather than direct D2 receptor binding
• Functional connectivity changes in amygdala-temporal cortex circuits, observed in resting-state fMRI studies in human participants

All mechanistic findings are from Selank as the parent compound. AC-Selank-NH2 has not been independently studied in indexed peer-reviewed literature. Data should be interpreted with caution and are not generalizable to human therapeutic outcomes.

What are the Potential Research Observations of AC-Selank-NH2 Peptide?

The following research findings are based on articles retrieved from PubMed and are reported from preclinical and in vitro studies of the parent compound Selank only. These findings do not constitute clinical evidence. AC-Selank-NH2 specifically has not been independently studied in PubMed-indexed literature.

GABA-A Receptor Allosteric Modulation in Experimental Models

Based on articles retrieved from PubMed, Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was studied for its molecular mechanisms of anxiolytic activity using radioligand-receptor analysis in rat brain membrane preparations. Selank was found to act as a positive allosteric modulator of GABA-A receptor binding. The joint action of Selank with benzodiazepines regulated GABA binding in a non-cumulative manner. Selank was also observed to block the modulatory activity of diazepam and olanzapine, suggesting partial overlap of binding sites. Findings are from rat experimental models only and have not been validated in human clinical studies.

Enkephalin-Degrading Enzyme Inhibition and Anxiolytic Activity in Stress Models

Based on articles retrieved from PubMed, Selank was studied in mice with different phenotypes of emotional and stress reactions. Administration of Selank at 100 micrograms/kg produced anxiolytic effects in the open-field test in BALB/c mice and was associated with increased half-life of plasma leu-enkephalin. These effects were not observed in C57Bl/6 mice, suggesting a phenotype-dependent response. The authors proposed that the anxiolytic activity of Selank is associated with the inhibition of enkephalin-degrading enzymes. Findings are from a mouse experimental model and are not generalizable to human outcomes.

Note: AC-Selank-NH2 (N-Acetyl Selank Amidate) is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It has no approved therapeutic indications. This compound is intended strictly for scientific research purposes only.

Safety Profile and Toxicological Considerations

Researchers have noted the following observations in experimental settings. Long-term safety data remain absent for both Selank and AC-Selank-NH2. A complete toxicity profile has not been established in any biological system for the AC-NH2 modified form.

• No LD50 or chronic toxicity data are available in peer-reviewed literature for AC-Selank-NH2 specifically
• No human safety profile exists for AC-Selank-NH2; systemic effects of inadvertent exposure are not established
• The N-acetylation and C-terminal amidation modifications alter enzymatic degradation profiles — pharmacokinetic implications in human systems are unknown
• Reconstituted solutions should be used promptly; repeated freeze-thaw cycles are associated with reduced peptide integrity
• Interactions with GABAergic and opioidergic systems observed in preclinical Selank studies suggest potential for off-target signaling effects outside targeted experimental contexts
• Receptor pharmacology data specific to AC-Selank-NH2 in any biological system are absent

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Preclinical research involving animals must comply with IACUC directives under the Animal Welfare Act (AWA).

Why Choose RCDbio for AC-Selank-NH2?

If you are looking to source research-grade AC-Selank-NH2 peptide, RCDbio offers third-party tested compounds available strictly for preclinical and in vitro research use. Each batch is held to standard quality protocols, and a Certificate of Analysis (COA) is available per lot.

• Independent third-party laboratory testing per batch
• COA confirming compound identity and purity per lot
• Molecular identity confirmed against CAS 2212313-10-6 (N-Acetyl Selank Amidate) 
• RCDbio does not self-certify; all quality verification is conducted by accredited independent laboratories

Disclosure: Sponsored by RCDbio. This content is for informational purposes only and does not constitute an endorsement of any product for human use.

FREQUENTLY ASKED QUESTIONS

Is AC-Selank-NH2 approved for human use?

No. AC-Selank-NH2 is not approved by the FDA for any human or medical application. It is classified as a research-use peptide only and has no approved therapeutic indications in any regulatory jurisdiction.

What is the difference between Selank and AC-Selank-NH2?

AC-Selank-NH2 incorporates two structural modifications relative to the parent Selank molecule: N-terminal acetylation (Ac-) and C-terminal amidation (-NH2). These modifications are associated with increased resistance to aminopeptidase and carboxypeptidase degradation, respectively, potentially improving enzymatic stability in experimental systems.

What signaling pathways does Selank propose to interact with in research models?

Based on articles retrieved from PubMed, Selank is proposed to act as a positive allosteric modulator of GABA-A receptors and to inhibit enkephalin-degrading enzymes in preclinical models. Dopaminergic system modulation has also been observed, proposed to operate through the endogenous opioid system. All findings are from preclinical animal models or controlled human studies of the parent Selank compound only.

How should AC-Selank-NH2 be stored in a laboratory setting?

Lyophilized AC-Selank-NH2 should be stored at −20 °C in a dry, dark environment, away from heat, moisture, and light. Reconstituted solutions should be used promptly following validated laboratory protocols. Repeated freeze-thaw cycles should be avoided to maintain peptide integrity.

What is the shelf life of AC-Selank-NH2 peptide?

When stored lyophilized at −20 °C under recommended conditions, AC-Selank-NH2 peptide is estimated to remain stable for up to 24 months.

References

Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642

Sokolov, O. Yu., Meshavkin, V. K., Kost, N. V., & Zozulya, A. A. (2002). Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bulletin of Experimental Biology and Medicine, 133(2), 133–135. https://doi.org/10.1023/a:1015582302311

Meshavkin, V. K., Kost, N. V., Sokolov, O. Yu., Zolotarev, Yu. A., Myasoedov, N. F., & Zozulya, A. A. (2006). Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of the dopamine system. Bulletin of Experimental Biology and Medicine, 142(5), 598–600. https://doi.org/10.1007/s10517-006-0428-1

Disclaimer

AC-Selank-NH2 (N-Acetyl Selank Amidate) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition. The Food and Drug Administration has not evaluated the statements on this page. Researchers must comply with all applicable local laws and regulations governing the use of research compounds. Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Preclinical research involving animals must comply with IACUC directives under the Animal Welfare Act (AWA). By purchasing, you agree to RCDbio Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.